❭ Medical divisions ❭ Cancer Medicine ❭ Dept. of Oncology ❭ Cellular therapy ❭ Innovations and Technology ❭
  • Search
  • Publication search
  • Print page

We have some technologies available for exclusive licensing or industrial collaboration. Our TTO (Inven2) will answer all your questions about:  

  • TCR-CAR

  • CD37CAR

Car t-cell therapy

  • Dual CAR IGK-CD19

  • CAR against osteosarcoma, OSCAR

 

 
Page visits: 96

Home Dept. of Oncology Cellular therapy

  • News
  • Contact Clinical Ward
  • Contact Translational Research Unit
  • Immunomonitoring Unit
  • Publications
  • Vacant positions
  • External collaborators
  • Innovations and Technology

Recent publications

Köksal H, Dillard P, Juzeniene A, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2020)
Combinatorial CAR design improves target restriction
J Biol Chem, 100116 (in press)
DOI 10.1074/jbc.RA120.016234, PubMed 33434588

Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, Juul HV, Aamdal S, Gaudernack G, Inderberg EM (2020)
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Front Immunol, 11, 572172
DOI 10.3389/fimmu.2020.572172, PubMed 33324397

Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2020)
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther (in press)
DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301

More publications

Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority.

Webmaster for research pages: Trond Olav Berg

Email: trond.olav.berg@rr-research.no

Cookie policy